Document Detail


Pitrakinra for asthma.
MedLine Citation:
PMID:  20923253     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: In asthma IL-4 and IL-13 have been demonstrated to play major pathogenic roles and therefore their blockade would potentially represent a plausible therapeutic approach.
AREAS COVERED IN THIS REVIEW: Pitrakinra is a dual IL-4/IL-13 inhibitor currently under development for asthma and the existing preclinical and clinical data are discussed.
WHAT THE READER WILL GAIN: Inhaled pitrakinra demonstrated a good anti-inflammatory potential and a good safety profile on a short-term basis but its place in asthma therapy is still to be found.
TAKE HOME MESSAGE: Specific anticytokine therapies might in the near future reshape asthma therapy.
Authors:
Sabina A Antoniu; Ileana Cojocaru
Related Documents :
3936563 - Mediators and asthma.
20415863 - 99th dahlem conference on infection, inflammation and chronic inflammatory disorders: f...
11769963 - Cytokine deregulation in cancer.
Publication Detail:
Type:  Journal Article     Date:  2010-10-05
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  10     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1609-15     Citation Subset:  IM    
Affiliation:
Department of Medicine II -Pulmonary Disease, Gr T Popa University of Medicine and Pharmacy Iaşi, Pulmonary Disease University Hospital, 30 Dr I Cihac Str, 700115 Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thermodynamic descriptors, profiles and driving forces in membrane receptor-ligand interactions.
Next Document:  Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon.